See more : Ichigo Inc. (2337.T) Income Statement Analysis – Financial Results
Complete financial analysis of Biotricity, Inc. (BTCY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biotricity, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Odakyu Electric Railway Co., Ltd. (9007.T) Income Statement Analysis – Financial Results
- Just Eat Takeaway.com N.V. (GRUB) Income Statement Analysis – Financial Results
- Dayang Enterprise Holdings Bhd (5141.KL) Income Statement Analysis – Financial Results
- Seika Corporation (8061.T) Income Statement Analysis – Financial Results
- Godrej Industries Limited (GODREJIND.NS) Income Statement Analysis – Financial Results
Biotricity, Inc. (BTCY)
About Biotricity, Inc.
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.06M | 9.64M | 7.65M | 3.38M | 1.42M | 398.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.71M | 4.20M | 3.08M | 2.11M | 931.95K | 338.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 8.36M | 5.44M | 4.57M | 1.27M | 485.77K | 59.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 69.27% | 56.46% | 59.74% | 37.60% | 34.26% | 15.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.57M | 3.23M | 2.74M | 2.06M | 1.36M | 1.31M | 1.76M | 1.14M | 1.14M | 23.20K | 53.60K |
| General & Administrative | 14.61M | 17.62M | 18.56M | 12.57M | 10.05M | 7.34M | 5.96M | 4.80M | 3.99M | 56.09K | 29.25K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.61M | 17.62M | 18.56M | 12.57M | 10.05M | 7.34M | 5.96M | 4.80M | 3.99M | 56.09K | 29.25K |
| Other Expenses | 0.00 | -181.94K | -1.14M | -67.10K | 16.94K | 0.00 | 0.00 | 0.00 | 0.00 | -1.22K | -1.15K |
| Operating Expenses | 17.18M | 20.85M | 21.31M | 14.62M | 11.42M | 8.65M | 7.72M | 5.94M | 5.13M | 89.60K | 89.92K |
| Cost & Expenses | 20.89M | 25.05M | 24.39M | 16.74M | 12.35M | 8.99M | 7.72M | 5.94M | 5.13M | 89.60K | 89.92K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.19M | 2.58M | 10.57M | 2.48M | 92.42K | 0.00 | 879.42K | 1.18M | 59.88K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.95K | 346.26K | 68.34K | 347.12K | 148.76K | 8.58M | 7.72M | 5.94M | 9.05K | 810.00 | 1.15K |
| EBITDA | -8.90M | -15.40M | -18.02M | -13.35M | -10.93M | -8.59M | 0.00 | -5.94M | -5.12M | 0.00 | -89.92K |
| EBITDA Ratio | -73.75% | -161.69% | -233.65% | -396.45% | -769.81% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.83M | -15.59M | -17.88M | -13.42M | -10.91M | -8.59M | -7.72M | -5.94M | -5.13M | -90.41K | -91.07K |
| Operating Income Ratio | -73.18% | -161.75% | -233.68% | -396.45% | -769.81% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.27M | -3.25M | -12.39M | -2.78M | -136.26K | 0.00 | -900.00K | -1.87M | -55.85K | 7.00 | 0.00 |
| Income Before Tax | -14.09M | -18.66M | -29.13M | -15.49M | -11.07M | -8.59M | -8.62M | -7.81M | -5.19M | -90.81K | -91.07K |
| Income Before Tax Ratio | -116.84% | -193.57% | -380.78% | -457.67% | -780.61% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.40M | 9.43M | 2.07M | -39.41K | -171.86K | -6.84M | -4.76M | 50.82K | -810.00 | -1.15K |
| Net Income | -14.09M | -18.66M | -29.13M | -15.49M | -11.07M | -8.59M | -8.62M | -7.81M | -5.19M | -90.81K | -91.07K |
| Net Income Ratio | -116.84% | -193.57% | -380.78% | -457.67% | -780.61% | -2,157.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.66 | -2.15 | -3.85 | -2.48 | -1.85 | -1.54 | -1.72 | -1.81 | -1.42 | -0.06 | -0.06 |
| EPS Diluted | -1.66 | -2.15 | -3.85 | -2.48 | -1.85 | -1.54 | -1.72 | -1.81 | -1.42 | -0.06 | -0.06 |
| Weighted Avg Shares Out | 8.99M | 8.66M | 7.57M | 6.25M | 5.99M | 5.56M | 5.03M | 4.31M | 3.64M | 1.50M | 1.50M |
| Weighted Avg Shares Out (Dil) | 8.99M | 8.66M | 7.57M | 6.25M | 5.99M | 5.56M | 5.03M | 4.31M | 3.64M | 1.50M | 1.50M |
Biotricity Announces Continued Margin Improvement Driven by its Proprietary AI Cloud
REDWOOD CITY, CA / ACCESSWIRE / July 22, 2024 / Biotricity Inc. (Nasdaq:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced ongoing improvements in operational efficiency, scalability and margin performance driven by...
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July...
Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (Nasdaq:BTCY) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July...
Biotricity Announces Accelerated Path to EBITDA Positive
REDWOOD CITY, CA / ACCESSWIRE / July 11, 2024 / Biotricity Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its accelerated timeline to achieving EBITDA positive. The company now expects...
Biotricity Adds 60-Site, Multi-State Hospital Cardiac Monitoring Pilot Program
REDWOOD CITY, CA / ACCESSWIRE / July 10, 2024 / Biotricity Inc. (Nasdaq:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced the launch of a new cardiac monitoring pilot program with a...
Biotricity Launches HeartSecure: Immediate, At-Home Cardiac Screening Now Available
Democratizing cardiac health with convenient, rapid, and reliable results REDWOOD CITY, CA / ACCESSWIRE / June 28, 2024 / Biotricity Inc. (NASDAQ:BTCY), a forerunning Technology-as-a-Service (TaaS) company committed to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions,...
Biotricity, Inc. (BTCY) Q4 2024 Earnings Call Transcript
Biotricity, Inc. (NASDAQ:BTCY ) Q4 2024 Earnings Conference Call June 27, 2024 4:30 PM ET Company Participants Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - CFO Conference Call Participants Michael Donovan - H.C. Wainwright Operator Greetings, and welcome to...
Biotricity Reports Strong Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses for Fiscal Year 2024, Accelerating the Company's Path to Profitability
FY24 revenue up 25.2% YOY FY24 margins improved 1280 basis points to 69.3%, from 56.5% in the prior year; Q4-FY24 margins improved to 71.5%; margin expansion forecasted to continue FY24 operating expenses lower by 17.6% YOY Negative EBITDA reduced by...
Biotricity to Host Fourth Quarter and Fiscal Year 2024 Financial Results and Business Update Call on June 27
REDWOOD CITY, CA / ACCESSWIRE / June 26, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its fourth quarter and...
Biotricity Launches Direct-to-Consumer Heart Health Screening Service, HeartSecure, Making Heart Health Services Accessible in Response to the #1 Global Killer, Poising Company to Access the Growing Home Diagnostics Market
REDWOOD CITY, CA / ACCESSWIRE / June 12, 2024 / Biotricity Inc. (NASDAQ:BTCY), a forerunning Technology-as-a-Service (TaaS) company committed to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, today announces the highly anticipated launch of its direct-to-consumer...
Source: https://incomestatements.info
Category: Stock Reports